Keeton T K, Hall J S, Biediger A M
J Cardiovasc Pharmacol. 1987 Mar;9(3):356-62. doi: 10.1097/00005344-198703000-00012.
The subcutaneous administration of a single dose of the beta-adrenoceptor antagonists atenolol, betaxolol, oxprenolol, pindolol, propranolol, or sotalol to conscious spontaneously hypertensive rats (SHR) lowered mean arterial pressure (MAP) by 15-20%, but this vaso-depression was not accompanied by a rise in plasma norepinephrine (NE) concentration. When MAP was decreased at the same rate and to the same extent with the vasodilator minoxidil, plasma NE concentration increased 50-75%. Atenolol, betaxolol, propranolol, and sotalol lowered heart rate, whereas oxprenolol, pindolol, and minoxidil elicited a tachycardia. Atenolol (-48%), betaxolol (-63%), and propranolol (-29%) significantly suppressed plasma renin activity (PRA), and minoxidil elevated PRA by 150-315%. Pindolol (+37%) caused a nonsignificant increase in PRA, and oxprenolol (-23%) and sotalol (-17%) produced nonsignificant decreases in PRA. Because the beta-adrenoceptor antagonists did not increase plasma NE concentration, whereas an equivasodepressor dose of minoxidil did, we conclude that plasma NE concentration is inappropriately low relative to the decrease in MAP caused by beta-adrenoceptor antagonists in the conscious SHR. In addition, the diverse effects of the beta-adrenoceptor antagonists on PRA in SHRs indicate that a suppression of renin release cannot account for either the decrease in MAP caused by these drugs or the failure of plasma NE concentration to increase when MAP is decreased by beta-adrenoceptor antagonists.
给清醒的自发性高血压大鼠(SHR)皮下注射单剂量的β-肾上腺素能受体拮抗剂阿替洛尔、倍他洛尔、氧烯洛尔、吲哚洛尔、普萘洛尔或索他洛尔,可使平均动脉压(MAP)降低15%-20%,但这种血管抑制并未伴随血浆去甲肾上腺素(NE)浓度升高。当用血管扩张剂米诺地尔以相同速率和相同程度降低MAP时,血浆NE浓度升高50%-75%。阿替洛尔、倍他洛尔、普萘洛尔和索他洛尔可降低心率,而氧烯洛尔、吲哚洛尔和米诺地尔则引起心动过速。阿替洛尔(-48%)、倍他洛尔(-63%)和普萘洛尔(-29%)显著抑制血浆肾素活性(PRA),米诺地尔使PRA升高150%-315%。吲哚洛尔(+37%)使PRA有不显著的升高,氧烯洛尔(-23%)和索他洛尔(-17%)使PRA有不显著的降低。由于β-肾上腺素能受体拮抗剂不会增加血浆NE浓度,而等效血管减压剂量的米诺地尔会增加,我们得出结论,相对于清醒SHR中β-肾上腺素能受体拮抗剂引起的MAP降低,血浆NE浓度过低。此外,β-肾上腺素能受体拮抗剂对SHR中PRA的不同影响表明,肾素释放的抑制既不能解释这些药物引起的MAP降低,也不能解释当β-肾上腺素能受体拮抗剂降低MAP时血浆NE浓度未能升高的原因。